[HTML][HTML] Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer

M Alexander, R Wolfe, D Ball, M Conron… - British journal of …, 2017 - nature.com
Methods: Prospective registry and study data were analysed using Cox proportional hazards
regression to derive a prognostic model (hospital 1, n= 695), which was subsequently …

Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma

M Alexander, JD Mellor, G McArthur… - Medical Journal of …, 2014 - Wiley Online Library
Objectives: To evaluate the efficacy and tolerability of ipilimumab in an Australian clinical
setting, and to assess the association of response with melanoma subtype, BRAF mutation …

[HTML][HTML] A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies

CW Guo, M Alexander, Y Dib, PKH Lau… - European journal of …, 2020 - Elsevier
Immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) have transformed the
management of many malignancies. Although rare, immune-mediated myocarditis presents …

A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based …

S Glewis, M Alexander, MNH Khabib… - British Journal of …, 2022 - nature.com
Background Serious and potentially life-threatening toxicities can occur following 5-fluorouracil/capecitabine
exposure. Patients carrying Dihydropyrimidine Dehydrogenase (DPYD) …

A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies

S Maleki, M Alexander, T Fua, C Liu… - Journal of Oncology …, 2019 - journals.sagepub.com
Background Patients receiving anticancer therapies are frequently prescribed complex and
high-risk medication regimens, which at times can result in medication misadventures. The …

Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer

W Cui, F Franchini, M Alexander, A Officer, HL Wong… - Lung Cancer, 2020 - Elsevier
Background KRAS mutations are found in 20–30 % of non-small cell lung cancers (NSCLC)
and were traditionally considered undruggable. KRAS G12C mutation confers sensitivity to …

Evaluation of an artificial intelligence clinical trial matching system in Australian lung cancer patients

M Alexander, B Solomon, DL Ball, M Sheerin… - JAMIA …, 2020 - academic.oup.com
Objective The objective of this technical study was to evaluate the performance of an
artificial intelligence (AI)-based system for clinical trials matching for a cohort of lung cancer …

EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer

JL Leal, M Alexander, M Itchins, GM Wright, S Kao… - Clinical lung cancer, 2021 - Elsevier
Background Epidermal growth factor receptor gene (EGFR) exon 20 insertion (ex20-ins)
mutations are an uncommon and heterogeneous group of non–small cell lung cancers (…

Risk-directed ambulatory thromboprophylaxis in lung and gastrointestinal cancers: the TARGET-TP randomized clinical trial

M Alexander, S Harris, C Underhill, J Torres… - JAMA …, 2023 - jamanetwork.com
Importance Thromboprophylaxis for individuals receiving systemic anticancer therapies has
proven to be effective. Potential to maximize benefits relies on improved risk-directed …

Timely initiation of chemotherapy: a systematic literature review of six priority cancers–results and recommendations for clinical practice

M Alexander, R Blum, K Burbury… - Internal Medicine …, 2017 - Wiley Online Library
… Project funding included the appointment of Marliese Alexander and Natalie Love as
project officers. Marliese Alexander was additionally supported by the Australian Postgraduate …